Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cannabidiol seizure:

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. Devinsky O et al. N Engl J Med. (2017)

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. Devinsky O et al. N Engl J Med. (2017)

Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Kaplan JS et al. Proc Natl Acad Sci U S A. (2017)

Search results

Items: 1 to 20 of 184

1.

Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.

Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B, Devinsky O, Checketts D, Roberts C.

Epilepsia. 2019 Feb 11. doi: 10.1111/epi.14670. [Epub ahead of print]

PMID:
30740695
2.

A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.

White CM.

J Clin Pharmacol. 2019 Feb 7. doi: 10.1002/jcph.1387. [Epub ahead of print] Review.

PMID:
30730563
3.

An Update of Current Cannabis-Based Pharmaceuticals in Pain Medicine.

Urits I, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O.

Pain Ther. 2019 Feb 5. doi: 10.1007/s40122-019-0114-4. [Epub ahead of print] Review.

PMID:
30721403
4.

Are there mortality risks for patients with epilepsy who use cannabis treatments as monotherapy?

Kollmyer DM, Wright KE, Warner NM, Doherty MJ.

Epilepsy Behav Case Rep. 2018 Dec 3;11:52-53. doi: 10.1016/j.ebcr.2018.11.007. eCollection 2019.

5.

US Veterinarians' Knowledge, Experience, and Perception Regarding the Use of Cannabidiol for Canine Medical Conditions.

Kogan L, Schoenfeld-Tacher R, Hellyer P, Rishniw M.

Front Vet Sci. 2019 Jan 10;5:338. doi: 10.3389/fvets.2018.00338. eCollection 2018.

6.

Cannabidiol modulates phosphorylated rpS6 signalling in a zebrafish model of Tuberous Sclerosis Complex.

Serra I, Scheldeman C, Bazelot M, Whalley BJ, Dallas ML, de Witte PAM, Williams CM.

Behav Brain Res. 2019 Jan 23;363:135-144. doi: 10.1016/j.bbr.2019.01.040. [Epub ahead of print]

PMID:
30684511
7.

Preclinical safety and efficacy of cannabidivarin for early life seizures.

Huizenga MN, Sepulveda-Rodriguez A, Forcelli PA.

Neuropharmacology. 2019 Jan 10;148:189-198. doi: 10.1016/j.neuropharm.2019.01.002. [Epub ahead of print]

PMID:
30633929
8.

Why marijuana is headed for the mainstream.

Reinke T.

Manag Care. 2018 Dec;27(12):31.

9.

Epidiolex (Cannabidiol): A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.

Chen JW, Borgelt LM, Blackmer AB.

Ann Pharmacother. 2019 Jan 8:1060028018822124. doi: 10.1177/1060028018822124. [Epub ahead of print]

PMID:
30616356
10.

Multigenerational consequences of early-life cannabinoid exposure in zebrafish.

Carty DR, Miller ZS, Thornton C, Pandelides Z, Kutchma ML, Willett KL.

Toxicol Appl Pharmacol. 2019 Feb 1;364:133-143. doi: 10.1016/j.taap.2018.12.021. Epub 2018 Dec 27.

PMID:
30594692
11.

Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models.

Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn S, Sandhu H, Jones N, Bazelot M, Williams CM, McNeish AJ.

Epilepsia. 2019 Feb;60(2):303-314. doi: 10.1111/epi.14629. Epub 2018 Dec 26.

PMID:
30588604
12.

Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.

Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, Roberts C.

Epilepsia. 2019 Feb;60(2):294-302. doi: 10.1111/epi.14628. Epub 2018 Dec 23.

PMID:
30582156
13.

Cannaboinoid Antiemetic Therapy.

Taylor BN, Sauls RS.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Dec 21.

14.

Treatment of infantile spasms.

Hussain SA.

Epilepsia Open. 2018 Oct 23;3(Suppl Suppl 2):143-154. doi: 10.1002/epi4.12264. eCollection 2018 Dec.

15.

Simultaneous quantification of thirteen cannabinoids and metabolites in human plasma by liquid chromatography tandem mass spectrometry in adult epilepsy patients.

Roslawski MJ, Remmel RP, Karanam A, Leppik IE, Marino SE, Birnbaum AK.

Ther Drug Monit. 2018 Dec 4. doi: 10.1097/FTD.0000000000000583. [Epub ahead of print]

PMID:
30520828
16.

Cannabis-based products for pediatric epilepsy: A systematic review.

Elliott J, DeJean D, Clifford T, Coyle D, Potter BK, Skidmore B, Alexander C, Repetski AE, Shukla V, McCoy B, Wells GA.

Epilepsia. 2019 Jan;60(1):6-19. doi: 10.1111/epi.14608. Epub 2018 Dec 4.

PMID:
30515765
17.

Emerging drugs for the treatment of Dravet syndrome.

Brigo F, Striano P, Balagura G, Belcastro V.

Expert Opin Emerg Drugs. 2018 Nov 27. doi: 10.1080/14728214.2018.1552937. [Epub ahead of print]

PMID:
30482063
18.

Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.

Sands TT, Rahdari S, Oldham MS, Caminha Nunes E, Tilton N, Cilio MR.

CNS Drugs. 2019 Jan;33(1):47-60. doi: 10.1007/s40263-018-0589-2.

PMID:
30460546
19.

Epilepsy and Cannabis: A Literature Review.

Zaheer S, Kumar D, Khan MT, Giyanwani PR, Kiran F.

Cureus. 2018 Sep 10;10(9):e3278. doi: 10.7759/cureus.3278. Review.

20.

Efficacy of cannabinoids in paediatric epilepsy.

Ali S, Scheffer IE, Sadleir LG.

Dev Med Child Neurol. 2019 Jan;61(1):13-18. doi: 10.1111/dmcn.14087. Epub 2018 Nov 6. Review.

PMID:
30402932

Supplemental Content

Loading ...
Support Center